Cargando…
EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma
The CXC chemokine receptor 4 (CXCR4) exerts a variety of functions at different steps of hepatocellular carcinoma (HCC) progression. The molecular mechanisms and therapeutic value of CXCR4 in the development of HCC remain undefined. Here we show that aberrant CXCR4 overexpression is associated with...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Pub. Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598861/ https://www.ncbi.nlm.nih.gov/pubmed/26404566 http://dx.doi.org/10.1038/ncomms9494 |
_version_ | 1782394144476364800 |
---|---|
author | Liu, Haiou Liu, Yidong Liu, Weisi Zhang, Weijuan Xu, Jiejie |
author_facet | Liu, Haiou Liu, Yidong Liu, Weisi Zhang, Weijuan Xu, Jiejie |
author_sort | Liu, Haiou |
collection | PubMed |
description | The CXC chemokine receptor 4 (CXCR4) exerts a variety of functions at different steps of hepatocellular carcinoma (HCC) progression. The molecular mechanisms and therapeutic value of CXCR4 in the development of HCC remain undefined. Here we show that aberrant CXCR4 overexpression is associated with poor prognosis and aggressive characteristics of HCC. Suppression of CXCR4 activity via CXCR4 knockdown, AMD3100 or neutralizing antibody administration inhibits hepatoma cell tumorigenesis in vitro and in vivo. CXCR4 overexpression displays the opposite effects. Using Mir library screening we identify miR-622 as a regulator of CXCR4. Further studies show that miR-622 directly target the 3′ untranslated region of CXCR4 and is transcriptionally repressed by EZH2-induced H3K27 trimethylation and promoter methylation. EZH2/miR-622 promotes tumorigenesis through CXCR4. EZH2-mediated loss of miR-622 is found to correlate with CXCR4 overexpression and unfavourable prognosis in HCC patients. This study establishes EZH2/miR-622/CXCR4 as a potential adverse prognostic factor and therapeutic target for HCC patients. |
format | Online Article Text |
id | pubmed-4598861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Nature Pub. Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-45988612015-10-21 EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma Liu, Haiou Liu, Yidong Liu, Weisi Zhang, Weijuan Xu, Jiejie Nat Commun Article The CXC chemokine receptor 4 (CXCR4) exerts a variety of functions at different steps of hepatocellular carcinoma (HCC) progression. The molecular mechanisms and therapeutic value of CXCR4 in the development of HCC remain undefined. Here we show that aberrant CXCR4 overexpression is associated with poor prognosis and aggressive characteristics of HCC. Suppression of CXCR4 activity via CXCR4 knockdown, AMD3100 or neutralizing antibody administration inhibits hepatoma cell tumorigenesis in vitro and in vivo. CXCR4 overexpression displays the opposite effects. Using Mir library screening we identify miR-622 as a regulator of CXCR4. Further studies show that miR-622 directly target the 3′ untranslated region of CXCR4 and is transcriptionally repressed by EZH2-induced H3K27 trimethylation and promoter methylation. EZH2/miR-622 promotes tumorigenesis through CXCR4. EZH2-mediated loss of miR-622 is found to correlate with CXCR4 overexpression and unfavourable prognosis in HCC patients. This study establishes EZH2/miR-622/CXCR4 as a potential adverse prognostic factor and therapeutic target for HCC patients. Nature Pub. Group 2015-09-25 /pmc/articles/PMC4598861/ /pubmed/26404566 http://dx.doi.org/10.1038/ncomms9494 Text en Copyright © 2015, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
spellingShingle | Article Liu, Haiou Liu, Yidong Liu, Weisi Zhang, Weijuan Xu, Jiejie EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma |
title | EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma |
title_full | EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma |
title_fullStr | EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma |
title_full_unstemmed | EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma |
title_short | EZH2-mediated loss of miR-622 determines CXCR4 activation in hepatocellular carcinoma |
title_sort | ezh2-mediated loss of mir-622 determines cxcr4 activation in hepatocellular carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4598861/ https://www.ncbi.nlm.nih.gov/pubmed/26404566 http://dx.doi.org/10.1038/ncomms9494 |
work_keys_str_mv | AT liuhaiou ezh2mediatedlossofmir622determinescxcr4activationinhepatocellularcarcinoma AT liuyidong ezh2mediatedlossofmir622determinescxcr4activationinhepatocellularcarcinoma AT liuweisi ezh2mediatedlossofmir622determinescxcr4activationinhepatocellularcarcinoma AT zhangweijuan ezh2mediatedlossofmir622determinescxcr4activationinhepatocellularcarcinoma AT xujiejie ezh2mediatedlossofmir622determinescxcr4activationinhepatocellularcarcinoma |